28942-54-3 Usage
General Description
METHYL 2-AMINO-5-ETHYL-1,3-THIAZOLE-4-CARBOXYLATE is a chemical compound with the molecular formula C8H11N3O2S. It is a thiazole derivative with a methyl ester functional group. METHYL 2-AMINO-5-ETHYL-1,3-THIAZOLE-4-CARBOXYLATE has potential applications in the pharmaceutical industry as it has been studied for its antiviral and antibacterial properties. It is also used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Additionally, it is a versatile building block for the preparation of other organic compounds. Overall, METHYL 2-AMINO-5-ETHYL-1,3-THIAZOLE-4-CARBOXYLATE is a valuable compound with diverse industrial and medicinal uses.
Check Digit Verification of cas no
The CAS Registry Mumber 28942-54-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,9,4 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 28942-54:
(7*2)+(6*8)+(5*9)+(4*4)+(3*2)+(2*5)+(1*4)=143
143 % 10 = 3
So 28942-54-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H10N2O2S/c1-3-4-5(6(10)11-2)9-7(8)12-4/h3H2,1-2H3,(H2,8,9)
28942-54-3Relevant articles and documents
Identification of potent type I MetAP inhibitors by simple bioisosteric replacement. Part 1: Synthesis and preliminary SAR studies of thiazole-4-carboxylic acid thiazol-2-ylamide derivatives
Cui, Yong-Mei,Huang, Qing-Qing,Xu, Jie,Chen, Ling-Ling,Li, Jing-Ya,Ye, Qi-Zhuang,Li, Jia,Nan, Fa-Jun
, p. 3732 - 3736 (2007/10/03)
A series of thiazole-4-carboxylic acid thiazol-2-ylamide (TCAT, 4) derivatives were designed and synthesized according to simple bioisosteric replacement from previously reported pyridine-2-carboxylic acid thiazol-2-ylamide (PCAT) MetAP inhibitors. The preliminary SAR studies demonstrated that these TCAT series of compounds showed different activity and selectivity compared with those of the corresponding PCAT compounds. These findings provide useful information for the design and discovery of more potent inhibitors of type I MetAPs.
